The landscape of precision cancer medicine clinical trials in the United States.

Purpose: Advances in tumor biology and multiplex genomic analysis have ushered in the era of precision cancer medicine. Little is currently known, however, about the landscape of prospective "precision cancer medicine" clinical trials in the U.S.

Adult cancer clinical trials that fail to complete: an epidemic?

The number and diversity of cancer therapeutics in the pipeline has increased over the past decade due to an enhanced understanding of cancer biology and the identification of novel therapeutic targets. At the same time, the cost of bringing new drugs to market and the regulatory burdens associated with clinical drug development have progressively increased. The finite number of eligible patients and limited financial resources available to evaluate promising new therapeutics represent rate-limiting factors in the effort to translate preclinical discoveries into the next generation of standard therapeutic approaches.

Dynamic Stokes shift of the time-resolved phosphorescence spectrum of Zn(II)-substituted cytochrome c.

The dynamic phosphorescence Stokes shift (PSS) response of Zn(II)-substituted cytochrome c (ZnCytc) was detected using the time-resolved phosphorescence spectrum of the intrinsic Zn(II)-porphyrin chromophore, which senses the motions of the surrounding protein and hydration shell. The phosphorescence spectrum of ZnCytc exhibits resolved vibronic structure arising from in-plane deformations of the porphyrin macrocycle, as is also observed in the absorption and fluorescence spectra. As the emission time increases, the phosphorescence spectrum shifts to the red without incurring a significant change in vibronic structure or line shape, so the shift arises from dynamic solvation, the reorganizational motions of the protein and solvent that occur in response to formation of the first excited triplet state.

Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.

Objectives: The independent prognostic effect of comorbidities on outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) is unclear. We sought to determine whether the Charlson comorbidity index (CCI) and hypertension (HTN) are associated with overall survival (OS) independent of known clinical prognostic factors in mCRPC.

Patients And Methods: A retrospective analysis was conducted on 221 patients with mCRPC treated with docetaxel plus prednisone combined with AT-101 (bcl-2 antagonist) or placebo on a prospective randomized phase II trial.

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group.

Background: There have been no improvements in the treatment of metastatic urothelial cancer in the past several decades. A census of contemporary clinical research in this disease was performed to identify potential barriers and opportunities.

Methods: These authors performed a search for clinical trials exploring interventions in muscle-invasive and metastatic urothelial cancer, using the ClinicalTrials.